Fig 4 - by Zixiang Wang (7548716)

S1 Data - by Zixiang Wang (7548716)

“…The two groups of rats were observed and compared for PVT formation at 1, 3 and 5 days after modeling, respectively.</p><p>Results</p><p>A stable rat PVT model was successfully constructed. …”

Characteristics of the study population according to physical activity at enrollment^b'*'. by Ronit Calderon-Margalit (584756)

BMD analysis of red cell count (A), hematocrit (B) and hemoglobin (C) in males (triangles) and females (circles). by Matti Viluksela (321291)

“…<p>These parameters were dose-dependently decreased in both genders. Small symbols indicate individual samples, large symbols the group mean; the vertical dotted line indicates the dose (CED) with 5% decrease (CES -0.05) compared to background (a parameter). …”

Select metabolites containing significant quantities of ¹³C after growth with ¹³C glucose^b'*'. by Javiera Norambuena (137228)

Meta-analysis of the effect of the G-allele of <i>FAF1</i>-rs17106184 on 2-hour serum insulin in 6,260 individuals from the Inter99 study (n = 5,547), ADIGEN controls (n = 246), AD... by Marie Neergaard Harder (232759)

Meta-analysis of the effect of the C-allele of <i>TMEM154</i>-rs6813195 on disposition index in 6,486 individuals from the Inter99 study (n = 5,181), Health 2008 study (n = 592), A... by Marie Neergaard Harder (232759)

Meta-analysis of the effect of the C-allele of <i>TMEM154</i>-rs6813195 on insulinogenic index in 6,486 individuals from the Inter99 study (n = 5,181), Health 2008 study (n = 592),... by Marie Neergaard Harder (232759)

Relevant information on key targets and biomarkers docking. by Ying Shen (48310)

Cu ions inhibit Prs. by Javiera Norambuena (137228)

Adverse events in low-dose naltrexone arm. by Judith I. Tsui (5983160)

“…</p><p>Clinical trial registration</p><p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT4052139" target="_blank">NCT4052139</a>).…”

CONSORT flow diagram. by Judith I. Tsui (5983160)

“…</p><p>Clinical trial registration</p><p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT4052139" target="_blank">NCT4052139</a>).…”

Adverse events in placebo arm. by Judith I. Tsui (5983160)

“…</p><p>Clinical trial registration</p><p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT4052139" target="_blank">NCT4052139</a>).…”

Adverse events in gabapentin arm. by Judith I. Tsui (5983160)

“…</p><p>Clinical trial registration</p><p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT4052139" target="_blank">NCT4052139</a>).…”

Copper detoxification contributes to <i>S</i>. <i>aureus</i> pathogenesis. by Javiera Norambuena (137228)

Time-dependent effects of pre-exposure to rotenone. by Joseph A. Covi (3131166)

T2D case-control analyses of up to 5,777 patients from Inter99 (n = 320), Health 2006 (n = 166), Health 2008 (n = 18), Steno Diabetes Center (n = 1,424), ADDITION (n = 1,870) and V... by Marie Neergaard Harder (232759)

Genetically altering the demand for PRPP modulates the sensitivity to Cu(II). by Javiera Norambuena (137228)

5-year persistence of innate immune responses to VZV-gE after RZV administration. Data were derived from 14 RZV recipients who received 2 doses of vaccine at Days 0 and 60. Demogra... by Michael J. Johnson (5818168)

Growth with Cu(II) alters pentose phosphate pathway function. by Javiera Norambuena (137228)